Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
Status:
Completed
Trial end date:
2017-01-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment
of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of
double-blind treatment and 52 weeks of open-label extension.